Drug Profile

C CAR 168

Alternative Names: C-CAR-168; CD20/BCMA-directed CAR-T cell therapy - AbelZeta Pharma

Latest Information Update: 06 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AbelZeta Pharma
Class CAR-T cell therapies; Gene therapies
Mechanism of Action T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Autoimmune disorders

Most Recent Events

27 May 2025 AbelZeta plans to request a type B meeting with the US FDA to discuss the next steps in the clinical and manufacturing development of C CAR168
27 May 2025 C CAR 168 receives Regenerative Medicine Advanced Therapy (RMAT) status for Systemic lupus erythematosus in USA
22 Apr 2025 AbelZeta plans a phase I/II trial for Lupus nephritis in USA (IV, Infusion) in July 2025 (NCT06935474)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com